|
| [February 06, 2013] |
 |
House Wellness Foods Corporation Unveils the Immunobiotic Ingredient "Immuno-LP20" for the North American Market
ITAMI, Japan --(Business Wire)--
House Wellness Foods Corporation starts the sales promotion of a
proprietary immunity ingredient "Immuno-LP20" in North America. House
Wellness Foods Corporation has positioned this ingredient as an
"Immunobiotica)" ingredient rather than a standard
"probiotic" ingredient with the goal for its widespread adoption in
supplements and foods applications.
Immuno-LP20 is the powder which contains heat-treated lactic acid
bacteria Lactobacillus plantarum L-137 (HK L-137). The L-137
strain was originally isolated from "a fermented fish and rice dish"
which is a traditional food in Asia.
HK L-137 powerfully induces the production of interleukin 12 (IL-12), a
cytokine which raises the T helper 1 (Th1) type immune response (often
referred to as cellular immunity). The anti-allergic and anti-tumor
effects of HK L-137 have been confirmed through animal testing.
Moreover, Th1/Th2 balance and T cell proliferation, which are index of
cellular immunity, were improved in human clinical trials. Human
clinical trials with HK L-137 also demonstrated an improvement in
quality of life (QOL)1).
The most recent clinical study demonstrates the ability of HK L-137 to
support the production of type I Interferon (IFN). Type I IFN inhibits
the multiplication of viruses. In testing with mice infected with H1N1
influenza, the influenza virus count decreased in mice through oral
administration of HK L-1372). Type I IFN production is also
increased in humans through ingestion of HK L-1373).
Through these results, HK L-137 is suggested to be effective in
protection against infectious diseases, such as viruses, through
augmentation of cellular immunity, and induction of type I IFN
production.
Thus, the effects of ingestion of HK L-137 on upper respiratory tract
infection (URTI also referred to as the common cold) and immune function
were investigated in the double-blinded, placebo-controlled randomized
trial.
In the trial 78 healthy people (33 men and 45 women with an average age
50.6 y) who felt severe psychological stressb) were divided
into two groups at random. One group ingested 1 tablet containing 10 mg
of HK L-137 and another ingested a placebo tablet daily for 12 weeks.
The T cell proliferation, an index of cellular immunity, was measured
before and after 4 weeks, 8 weeks and 12 weeks of ingestion. URTI was
investigated every day using a questionnaire (Wisconsin Upper
Respiratory Symptom Survey-21: WURSS-21).
As a result, incidence of URTI was significantly lower in HK L-137 group
as compared with the placebo group. The duration and severity of the
common cold and the number of days during which medication was required
also showed a significant negative correlation with the duration of HK
L-137 ingestion. Moreover, in the HK L-137 ingestion group, T cell
proliferation significantly increased as compared with the placebo group.
Through these new findings that daily ingestion of lactic acid bacteria
supports human cellular immunity and helps to prevent the common cold,
we look to propose its new application as an "Immunobiotic."
House Wellness Foods Corporation has shown that daily intake of HK L-137
decreases the incidence of upper respiratory tract infection (URTI) in
human clinical trial.
|
|
�
|
�
|
�
|
�
|
4 weeks
|
�
|
�
|
8 weeks
|
�
|
�
|
12 weeks
|
|
Incidence (number of cases)
|
�
|
�
|
Control
|
21
|
�
|
�
|
14
|
�
|
�
|
12
|
|
�
|
�
|
HK L-137
|
21
|
�
|
�
|
8
|
�
|
�
|
6
|